Chair(s): Merel Hellemons, David Baldwin
Session type: Experts interview
ARGYRIS TZOUVELEKIS
Session content
Pulmonary toxicity of new oncology drugs
Argyris Tzouvelekis
Replay
Slides
Argyris Tzouvelekis
Stefano Gasparini
Replay
Slides
Session aims
To review the incidence and risk factors of pulmonary toxicity associated with new oncology drugs, with particular focus on patients with pre-existing interstitial lung disease (ILD); to highlight the importance of early recognition, awareness, and close monitoring of high-risk groups; to emphasize the role of the multidisciplinary team (MDT) in the evaluation and management of suspected drug-induced pulmonary toxicity; to outline key steps in the diagnostic pathway, including exclusion of alternative diagnoses and severity stratification; to discuss current management strategies, particularly the role of oral corticosteroids, and the importance of appropriate dosing in the setting of immune checkpoint inhibitor–induced toxicity.